secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001367644-26-000019
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions appoints John D. Fowler, Jr. to board of directors effective March 1, 2026
--------------------------------------------------------------------------------

- Fowler appointed as Class II director and will serve on the Audit and Finance Committee.
- Receives initial RSU grant valued at $270,000 vesting in three equal annual installments.
- Annual compensation: $70,000 cash retainer, $15,000 committee fee, $270,000 equity award (prorated first year).
- Chairman Zsolt Harsanyi states Fowler's experience will support the company's ongoing turnaround and transformation.
- Fowler brings 30+ years in healthcare and finance, including senior roles at Wells Fargo, Deutsche Bank, and JPMorgan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000019/0001367644-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000019/ebs-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer